

Zhi-wei Lai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1107517/publications.pdf>

Version: 2024-02-01

8
papers

1,025
citations

1477746

6
h-index

1872312

6
g-index

8
all docs

8
docs citations

8
times ranked

3211
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>N</i> -acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2937-2946.	6.7	331
2	Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. <i>Lancet, The</i> , 2018, 391, 1186-1196.	6.3	290
3	HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1888-1897.	0.5	131
4	Mechanistic Target of Rapamycin Activation Triggers IL-4 Production and Necrotic Death of Double-Negative T Cells in Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2013, 191, 2236-2246.	0.4	123
5	Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin. <i>Metabolomics</i> , 2015, 11, 1157-1174.	1.4	123
6	Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome. <i>Clinical Immunology</i> , 2015, 158, 148-152.	1.4	27
7	BD-02...Blockade of the mechanistic target of rapamycin elicits rapid and lasting improvement of disease activity through restraining pro-inflammatory T cell lineage specification in patients with active SLE. , 2018, , .		0
8	Sirolimus for systemic lupus erythematosus – Authors' reply. <i>Lancet, The</i> , 2018, 392, 734.	6.3	0